BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing Pharmaceutical Investing
U.S. Food and Drug Administration Accepts Supplemental New Drug Application for CAMZYOS® in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy Pharmaceutical Investing
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers Pharmaceutical Investing
AbbVie's SKYRIZI® Receives Health Canada Approval as the First and Only Specific Interleukin-23 to Treat Moderately to Severely Active Crohn's Disease in Adults Pharmaceutical Investing
Albert Labs Files New International PCT Patent Application for scalable API manufacturing Pharmaceutical Investing
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference Pharmaceutical Investing
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination Pharmaceutical Investing
Trip to Treatment: Lobe Sciences CEO Touts Targeted Low Dosing for Better Patient Outcomes Pharmaceutical Investing
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma Pharmaceutical Investing
